MANCHESTER, England — Use of immunosuppressive drugs within 5 years of the onset of systemic sclerosis (SSc) did not lower patients’ risk for developing pulmonary arterial hypertension (PAH) but was associated with a significantly lower likelihood of death in patients with the complication, researchers reported at the British Society for Rheumatology (BSR) 2025 Annual Meeting. … Read more
TOPLINE: Type I interferon (IFN) score may effectively predict disease progression in limited cutaneous systemic sclerosis (lcSSc), with patients having a high IFN activity presenting worse clinical outcomes. METHODOLOGY: Researchers conducted a longitudinal retrospective analysis to investigate whether the serum IFN score could predict clinically meaningful progression in patients with lcSSc using a novel composite … Read more
Baricitinib can effectively treat polymyalgia rheumatica (PMR) without the use of oral glucocorticoids, according to results from a small, randomized, double-blind, placebo-controlled study. Among the 18 patients randomly assigned to the oral Janus kinase (JAK) inhibitor baricitinib, 14 achieved a C-reactive protein PMR activity score (CRP PMR-AS) of 10 or less after 12 weeks of … Read more